五源资本
@author-1780022938586
5Y News | AI Ultrasound Company Deepwise Technology Closes Nearly 100 Million Yuan Series B+ Round
The combination of AI software and portable ultrasound is set to transform the healthcare services industry.
5Y News | Kuaishou, a 5Y Capital portfolio company, lists on the Hong Kong Stock Exchange. Congratulations to Kuaishou!
Here's to Kuaishou — may it thrive endlessly, connect all things, and create more beauty and order!
5Y News｜Neox Biotech Completes $30 Million Series A Round, 5Y Capital Continues Support
Exploring the most cutting-edge drug modalities.
5Y News | 5Y Capital portfolio company Superparameter Technology completes $30 million Series A+ round
Transforming game content production through AI.
5Y View | Xiaoxiao Zhou, 5Y Capital: The Underlying Logic of Business Is Supply and Demand
Companies that can truly close the loop on supply-demand dynamics are the ones that change the world — but they are few and far between.
5Y News | Xinhuazhang, a 5Y Capital portfolio company, announces completion of Series A+ round
Accelerating the R&D push for EDA 2.0, with continued backing from 5Y Capital.
5Y News | Men's Grooming Brand "理然" Closes Nearly RMB 150 Million Series B Round
The next generation of male consumers is continuously evolving in their grooming and personal-image needs.
5Y News | 5Y Capital Portfolio Company StartDT (奇点云) Closes RMB 80 Million B2 Round
Openness and mutual success: building a new cloud-based, data-intelligent business together.
**Official Statement**
Statement on Illegal Fundraising Activities Conducted Under Our Company's Name
5Y Talk｜Kai Yu of Horizon Robotics: The "Crazy" You Others Saw, Now Starting to Be Believed
Our hope is to become the Intel of the robotics era — that has been Horizon Robotics' mission from day one.
5Y News｜Keep Closes $360 Million Series F Round, 5Y Capital Continues Backing
Exercise is just a Keep moment.
5Y News | Galixir Announces Completion of Tens of Millions of USD in Funding, with Continued Backing from 5Y Capital
Breaking the Bottleneck in New Drug R&D with "AI+"